NASDAQ:ARQT

Arcutis Biotherapeutics Competitors

$28.18
-0.50 (-1.74 %)
(As of 04/16/2021 11:04 AM ET)
Add
Compare
Today's Range
$27.99
Now: $28.18
$29.23
50-Day Range
$26.61
MA: $30.42
$35.04
52-Week Range
$17.51
Now: $28.18
$39.85
Volume957 shs
Average Volume243,240 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) Vs. ALLK, BPMC, PRGO, SDGR, GLPG, and BHVN

Should you be buying ARQT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Arcutis Biotherapeutics, including Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), Galapagos (GLPG), and Biohaven Pharmaceutical (BHVN).

Arcutis Biotherapeutics (NASDAQ:ARQT) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares Arcutis Biotherapeutics and Allakos' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.24
AllakosN/AN/A$-85,370,000.00($1.89)-55.73

Allakos is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Arcutis Biotherapeutics and Allakos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcutis Biotherapeutics00403.00
Allakos00403.00

Arcutis Biotherapeutics presently has a consensus price target of $54.6667, suggesting a potential upside of 93.99%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 72.32%. Given Arcutis Biotherapeutics' higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Allakos.

Insider & Institutional Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Arcutis Biotherapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcutis BiotherapeuticsN/A-81.74%-57.72%
AllakosN/A-29.18%-27.70%

Arcutis Biotherapeutics (NASDAQ:ARQT) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares Arcutis Biotherapeutics and Blueprint Medicines' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.24
Blueprint Medicines$66.51 million83.61$-347,690,000.00($7.27)-13.20

Arcutis Biotherapeutics has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Arcutis Biotherapeutics and Blueprint Medicines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcutis Biotherapeutics00403.00
Blueprint Medicines06812.67

Arcutis Biotherapeutics presently has a consensus price target of $54.6667, suggesting a potential upside of 93.99%. Blueprint Medicines has a consensus price target of $112.40, suggesting a potential upside of 17.14%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Blueprint Medicines.

Profitability

This table compares Arcutis Biotherapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcutis BiotherapeuticsN/A-81.74%-57.72%
Blueprint Medicines41.08%43.72%33.35%

Insider & Institutional Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Blueprint Medicines beats Arcutis Biotherapeutics on 9 of the 13 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares Perrigo and Arcutis Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.15$146.10 million$4.0310.29
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.24

Perrigo has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Perrigo and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Arcutis Biotherapeutics00403.00

Perrigo presently has a consensus price target of $52.00, suggesting a potential upside of 25.36%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 93.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Perrigo.

Profitability

This table compares Perrigo and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Insider & Institutional Ownership

82.7% of Perrigo shares are held by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Perrigo beats Arcutis Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares Schrödinger and Arcutis Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million63.99$-24,570,000.00N/AN/A
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.24

Schrödinger has higher revenue and earnings than Arcutis Biotherapeutics.

Analyst Ratings

This is a summary of recent ratings for Schrödinger and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Arcutis Biotherapeutics00403.00

Schrödinger presently has a consensus price target of $85.50, suggesting a potential upside of 9.36%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 93.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Schrödinger.

Profitability

This table compares Schrödinger and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Insider & Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Schrödinger on 5 of the 9 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares Galapagos and Arcutis Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.15$167.83 million$5.4614.46
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.24

Galapagos has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Galapagos and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210502.18
Arcutis Biotherapeutics00403.00

Galapagos presently has a consensus price target of $143.7273, suggesting a potential upside of 82.05%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 93.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Galapagos.

Profitability

This table compares Galapagos and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Insider & Institutional Ownership

11.2% of Galapagos shares are held by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Galapagos beats Arcutis Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares Biohaven Pharmaceutical and Arcutis Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.83
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.24

Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Biohaven Pharmaceutical and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Arcutis Biotherapeutics00403.00

Biohaven Pharmaceutical presently has a consensus price target of $96.4545, suggesting a potential upside of 29.37%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 93.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Biohaven Pharmaceutical.

Profitability

This table compares Biohaven Pharmaceutical and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Insider & Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Biohaven Pharmaceutical on 6 of the 10 factors compared between the two stocks.


Arcutis Biotherapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Allakos logo
ALLK
Allakos
1.7$105.33-2.7%$5.74 billionN/A-38.44Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95-0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48-0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18-0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95-0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56-1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06-1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08-1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06-2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28-1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83-2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74-4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99-2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11-1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40-1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07-1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37-0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23-3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65-0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57-0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88-5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27-1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22-6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43-1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10-2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18-4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50-2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28-3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88-1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76-3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93-0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50-0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89-4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96-0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33-2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10-2.4%$2.06 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$123.42-2.6%$2.03 billionN/A-11.15
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.07-4.0%$2.01 billion$410,000.00-5.88Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52-2.2%$2.00 billion$103.54 million-19.19Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$60.11-3.8%$2.00 billionN/A-25.58Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$4.93-1.6%$1.97 billion$429.76 million-98.58Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.15-0.9%$1.97 billionN/A-19.39
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.